The ras-binding domain of ral GDS-like protein-2 as a ras inhibitor in smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 305, Issue 4, 2003, Pages 934-940

  Fischer, Thomas H ^a,b   Brittain, Julie ^a   Trabalzini, Lorenza ^c   Banes, Albert J ^a   White, Gilbert C ^a,b   Smith, Carr J ^a,d   Nichols, Timothy C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Growth factor; Proliferation; Ral GDS like protein 2; Ras; Smooth muscle cells

Indexed keywords

CELL CYCLE PROTEIN; GROWTH FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PLATELET DERIVED GROWTH FACTOR; PROTEIN CDC 25; RAL GDS LIKE PROTEIN 2; RAL PROTEIN; RAP PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL LINE; CLONE; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC CODE; GENETIC TRANSFECTION; INHIBITION KINETICS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STRUCTURE; RAT; SEQUENCE HOMOLOGY; SMOOTH MUSCLE FIBER; STRUCTURE ANALYSIS;

EID: 0037566754     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00878-7     Document Type: Article

References (63)

1. Trahey M., McCormick F. A cytoplasmic protein stimulated normal N-ras p21 GTPase, but does not affect oncongenic mutants. Science. 238:1987;542-545.
2. Vojtek A., Hollenberg S., Cooper J. Mammalian ras interacts directly with the serine/threonine kinase raf. Cell. 74:1993;205-214.
3. Macdonald S., Crews C., Wu L., Driller J., Clark R., Erikson R., McCormick F. Reconstitution of the raf-1-MEK-ERK signal transduction pathway in vitro. Mol. Cell. Biol. 13:1993;6615-6620.
4. Finco T., Westwick J., Norris J., Beg A., Der C., Baldwin A. Oncogenic H-ras-induced signaling activates NF-kappa B transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272(24):1997;113-117.
5. Charkraborti S., Charkraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell. Signal. 10:1998;675-683.
6. Shuster C., Herman I. The mechanics of vascular cell motility. Microcirculation. 5:1998;239-257.
7. Eguchi S., Iwasaki H., Ueno H., Frank G., Motley E., Eguchi K., Marumo G., Hirata Y., Inagami T. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at ser(411) in vascular smooth muscle cells-possible requirement of epidermal growth factor receptor, ras, extracellular signal-regulated kinase and akt. J. Biol. Chem. 275:1999;36843-36851.
8. Cohen L., Pieterman E., van Leeuwen R., Du J., Negre-aminou P., Valentijn A., Overhand M., van der Marel G., van Boom J. Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein:farnesyl transferase. Biochem. Pharmacol. 57:1999;365-373.
9. Yang C., Chiu T., Wang C., Chien C., Hsiao L., Lin C., Tu M., Pan S. Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells. Cell. Signal. 12:2000;205-214.
10. Abe J., Berk B. Fyn and JAK2 mediate ras activation by reactive oxygen species. J. Biol. Chem. 274:1999;21003-21010.
11. Abe J., Okuda M., Huang Q., Yoshizumi M., Berk B. Reactive oxyge species active p90 ribosomal S6 via nfyn and ras. J. Biol. Chem. 275:2000;1739-1748.
12. Ramos K. Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. Annu. Rev. Pharmacol. Toxicol. 39:1999;243-265.
13. Iwasaki H., Eguchi S., Marumo F., Hirata Y. Mechanical stretch stimulates growth of vascular smooth muscle cells via epidermal growth factor receptor. Am. J. Physiol. Heart Circ. Physiol. 278:2000;H521-H529.
14. Li C., Hu Y., Sturm G., Xu Q. Ras/rac-dependent activation of p38 MAPKs in smooth muscle cells stimulated by mechanical stress. Circulation. 100:1999;2268.
15. Miyamoto T., Fox J. Autocrine signaling through ras prevents apoptosis in vascular smooth muscle cells in vitro. J. Biol. Chem. 275:2000;2825-2830.
16. Kouchi H., Nakamura K., Fushimi K., Sakaguchi M., Miyazaki M., Ohe T., Namba M. Manumycin A, inhibitor of ras farneysyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 264:1999;915-920.
17. Dumphy J., Linder M. Signaling function of protein palmitoylation. Biochim. Biophys. Acta. 1436:1998;245-250.
18. Zang F., Casey P. Protein prenylation: molecular mechanism and functional consequences. Annu. Rev. Biochem. 65:1996;241-256.
19. Peterson S., Trabalzini L., Brtva T., Fischer T., Altschuler D., Eduardo L., Der C., White G. Identification of a novel ralGDS-related protein as a candidate effector for ras and rap 1b. J. Biol. Chem. 271:1996;29903-29908.
20. Hofer F., Fields S., Schneider C., Martin S. Activated ras interacts with the ral guanine nucleotide dissociation stimulator. Proc. Natl. Acad. Sci. USA. 91:1994;11089-11093.
21. Kikuchi A., Demo S., Ye Z., Chen Y., Williams L. Ral GDS family members interact with the effector loop of ras p21. Mol. Cell. Biol. 14:1994;7483-7491.
22. Albright C., Giddings B., Liu J., Vito M., Weinberg R. Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPases. EMBO J. 12:1993;339-347.
23. Cantor S., Urano T., Feig L. Identification and characterization of Ral-binding protein-1, a potential downstream target of ral GTPases. Mol. Cell. Biol. 15:1995;4578-4584.
24. Kikuchi A., Williams L. Regulation of interaction of ras p21 with ral GDS and raf-1 by cyclic AMP-dependent protein kinase. J. Biol. Chem. 271:1996;588-594.
25. Dong Y., Skoultchi A., Pollard J. Efficient DNA transfection of quiescent mammalian cells using poly-L-ornithine. Nucleic Acids Res. 21:1996;771-772.
26. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;665-680.
27. Towbin H., Staehelin T., Gordon J. Proc. Natl. Acad. Sci. USA. 76:1976;4350-4354.
28. Kolch W., Heidecker G., Lloyd P., Rapp U. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 349:1991;426-428.
29. Troppmair J., Bruder J., Munoz H., Lloyd P., Kyriakis J., Banerjee P., Avruch J., Rapp U. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-o-tetradecanoylphorbol-13-acetate requires raf and is necessary for transformation. J. Biol. Chem. 9:1994;7030-7035.
30. Irani K., Herzlinger S., Finkel T. Ras proteins regulate multiple mitogenic pathways in A10 vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 202:1994;1252-1258.
31. Kitayama H., Sugimoto Y., Matsuzaki T., Ikawa Y., Noda M. A ras-related gene with transformation suppressor activity. Cell. 56:1989;77-84.
32. Zhang K., Papageorge A., Martin P., Vass W., Olah Z., Polakis P., McCormick F., Lowy D. Heterogeneous amino acids in ras and rap 1a specifying sensitivity to GAP proteins. Nature. 254:1991;1630-1633.
33. Frech M., John J., Pizon V., Chardin P., Tavitian A., Clark R., McCormick F., Wittinghofer A. Inhibition of GTPase activating protein stimulation of ras-p21 GTPase by the Krev-1 gene product. Science. 249:1990;169-171.
34. Kawata M., Kikuchi A., Hoshijima M., Yamamoto K., Hashimoto E., Yamaura H., Takai Y. Phosphorylation of smg p21, a ras p21-like GTP binding protein, by cyclic AMP-dependent protein kinase in a cell-free system and in response to prostaglandin E1 in intact human platelets. J. Biol. Chem. 264:1990;15688-15695.
35. White T., Lacal J., Reep B., Fischer T., Lapetina E., White G. Thrombolamban, the 22 kilodalton platelet substrate of cAMP-dependent protein kinase, is immunologically homologous with the Ras family of GTP-binding proteins. Proc. Natl. Acad. Sci. USA. 87:1990;758-762.
36. Graves L., Bornfeldt K., Raines E., Potts B., MacDonald S., Ross R., Krebs E. Protein kinase A antagonized platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 90:1993;10300-10304.
37. Stout R., Bierman E., Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ. Res. 36:1975;319-327.
38. Mann M., Gibbons G., Kernoff R., Diet F., Tsao P., Cooke J., Kaneda Y., Dzau V. Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA. 92:1995;4502-4506.
39. Chang M., Barr E., Lu M., Barton K., Leiden J. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268.
40. Chen D., Krasinski K., Chen D., Sylvester A., Chen J., Nisen P., Andres V. Down regulation of cyclin-dependent kinase 2 activity and cyclin a promoter activity in vascular smooth muscle cells by p27(KIP1), inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99:1997;2334-2341.
41. Chang M., Barr E., Seltzer J., Jiang Y., Nabel G., Nabel E., Parmacek M., Leiden J. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
42. Perlman H., Luo Z., Krasinski K., Le Roux A., Mahfoudi A., Smith R., Branellec D., Walsh K. Adenovirus-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis. Gene Ther. 6:1999;758-763.
43. Mann M., Whittemore A., Donaldson M., Belkin M., Conte M., Polak J., Orav E., Ehsam A., Dell'Acqua G., Dzau V. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, control trial. Lancet. 354:1999;1493-1498.
44. Simons M., Edelman E., DeKeyser J., Langer R., Rosenberg R. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
45. Deguchi J., Namba T., Hamada H., Nakaoka T., Abe J., Sato O., Miyata T., Makuuchi M., Kurokawa K., Takuwa Y. Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Ther. 6:1999;956-965.
46. Huynh T., Iaccarino G., Davies M., Svendsen E., Koch W., Hagen P., Koch W. G protein signaling and vein graft intimal hyperplasia-reduction of intimal hyperplasia in vein grafts by a G(beta gamma) inhibitor suggests a major role of G protein signaling in lesion development. Arterioscler. Thromb. Vasc. Biol. 18:1998;1275-1280.
47. Shears L., Kawaharada N., Tzeng E., Billiar T., Watkins S., Kovesdi I., Lizonova A., Pham S. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J. Clin. Invest. 100:1997;2035-2042.
48. Numaguchi Y., Naruse K., Harada M., Osanai H., Mokuno S., Murase K., Matsui H., Toki Y., Ito T., Okumura K., Hayakawa T. Prostacyclin synthase gene transfer accelerates reendothelialisation and inhibits neointima formation in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 19:1999;727-733.
49. Laitinen M., Hartikainen J., Hiltunen M.O., Eranen J., Kiviniemi M., Narvanen O., Makinen K., Manninen H., Syvanne M., Martin J.F., Laakso M., Yla-Herttuala S. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 11:2000;263-270.
50. Stein C., Martins I., Bavidson B. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockage. J. Gene Med. 2:2000;41-51.
51. Fan L., Zhang H., Chen Q., Wei E., Cai H. Expression of reverse cholesterol transport pathway associated protein genes in skeletal muscle. Acta Biochem. Biophys. 32:2000;109-114.
52. Brousseau M., Kauffman R., Herderick E., Demosky S.J., Evans W., Marcovina S., Santamarina-Fojo S., Brewer H., Hoeg J. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler. Thromb. Vas. Biol. 20:2000;450-458.
53. Athanasopoulos P., Dunckley M., Hassall D., Fabb S., Tagalakis A., Shepelmann S., Owen J., Dickson J. Gene therapy for atherosclerosis: a comparative study of adeno-associated virus (AAV) and conventional plasmid vectors encoding human apolipoprotein E (apoE) cDNAs. Atherosclerosis. 144:1999;93-94.
54. van Dijk K., van Vlijmen B., van der Zee A., van't Hof B., van der Boom H., Kobayashi K., Chan L., Havekes L., Hofker M. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 18:1998;7-12.
55. Excoffon K., Liu G., Miao L., Wilson J., McManus B., Semenkovich C., Coleman T., Benoit P., Duverger N., Branellec D., Denefle P., Hayden M., Lewis M. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 11:1997;2532-2539.
56. Morishita R., Higaki J., Tomita N., Kaneda Y., Ogihara T. Novel gene therapy strategy for atherosclerosis using ribozyme against apolipoprotein a gene. Atherosclerosis. 134:1997;41.
57. Waugh J., Kattash M., Li J., Yuksel E., Kuo M., Lussier M., Weinfeld A., Saxena R., Rabinovsky E., Thung S., Woo S., Shenaq S. Gene therapy to promote thromboresistance: local expression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc. Natl. Acad. Sci. USA. 96:1999;1065-1070.
58. Waugh J., Yuksel E., Li J., Kuo M., Hilfiker P., Kattash M.I., Saxena R., Geske R., Thung S., Shenaq S., Dake M., Woo S. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ. Res. 98:1999;2744-2752.
59. George S., Johnson J., Angelini G., Newby A., Baker A. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Hum. Gene Ther. 9:1998;867-877.
60. George S., Baker A., Angelini G., Newby C. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 5:1998;1552-1560.
61. Ohno T., Gordon D., San H., Pompili V., Imperiale M., Nabel B., Nabel E. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-784.
62. Trakeuchi M., Shichinohe T., Senmaru N., Miyamoto M., Fujita H., Takimoto M., Kondo S., Katoh H., Kuzumaki N. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther. 7:2000;518-526.
63. Roth J. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum. Gene Ther. 7:1996;875-889.